Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Far East Bio-Tec Co., Ltd. (6886:TWSE), powered by AI.
Far East Bio-Tec Co., Ltd. is currently trading at $47.90. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Far East Bio-Tec Co., Ltd. on Alpha Lenz.
View Far East Bio-Tec Co., Ltd.'s valuation metrics on Alpha Lenz.
“Far East Bio-Tec Co., Ltd.'s ROE is 10.9%. Explore profitability and growth together.”
Ask for details →Far East Bio-Tec Co., Ltd. is a biotechnology and health food company specializing in the manufacturing and sale of high-quality microalgae-based products, including organic chlorella, organic spirulina, and a broad range of nutritional and dietary supplements. The company has pioneered the use of microalgae in various applications, offering nutraceuticals, immune boosters, antiviral sprays, and pet supplements, and recently expanded into advanced formulations such as nattokinase and spore-forming probiotics using proprietary fermentation technologies. Far East Bio-Tec is recognized for its commitment to product safety and efficacy, with ISO 22000 and HACCP certifications, and over four decades of experience in the sector. It stands out in research and development, notably becoming the first company in Taiwan to secure an INCI designation for plant-derived microalgae exosomes, enabling its entry into the international skincare market with proprietary biotechnology ingredients. By integrating advanced biotechnology with food and wellness products, Far East Bio-Tec Co., Ltd. plays a significant role in the consumer staples sector, bridging the gap between traditional health foods and innovative biopharmaceutical applications in Asia and beyond.
“Far East Bio-Tec Co., Ltd.'s ROE is 10.9%. Explore profitability and growth together.”
Ask for details →Far East Bio-Tec Co., Ltd. (ticker: 6886) is a company listed on TWSE in the Consumer Defensive sector (Packaged Foods).
The current price is 47.9 with a P/E ratio of -x and P/B of -x.
ROE is 10.89% and operating margin is 17.08%. Annual revenue is $402M.